The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
Chugai Pharmaceutical said on July 4 that it has launched Hemlibra (emicizumab) in Taiwan for the routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.The drug has been previously available on…
To read the full story
Related Article
- Hemlibra Now Available in Taiwan
November 5, 2019
- Taiwan Expands Hemlibra Label into Non-VIII Inhibitor Carriers
October 31, 2019
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Datroway Accepted for European Review for 1st Line TNBC
December 19, 2025
- Recordati Snags Japan Rights to BMS’ Myelofibrosis Med Inrebic
December 19, 2025
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…